You are here:

elbasvir-grazoprevir (Zepatier)

Advice

following a full submission

elbasvir-grazoprevir (Zepatier®) is accepted for use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).

In patients with genotype 1a, 1b or 4, elbasvir-grazoprevir significantly increased sustained virologic suppression compared with a regimen containing a non-structural protein 5B (NS5B) inhibitor, an interferon and ribavirin.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of elbasvir-grazoprevir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Drug Details

Drug Name: elbasvir-grazoprevir (Zepatier)
SMC Drug ID: 1203/17
Manufacturer: MSD
Indication: Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 16 January 2017

Back